Corrigendum to “Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease” [Neurobiology of Disease, 2024 Jan:190:106376]

• Stefan Bartl,
• Yuanyun Xie,
• Nalini Potluri,
• Ratnesh Kesineni,
• Katlin Hencak,
• Louisa Dal Cengio,
• Katja Balazs,
• Abid Oueslati,
• Michela Parth,
• Nina Salhat,
• Alberto Siddu,
• Oskar Smrzka,
• Francesca Cicchetti,
• Günther Staffler,
• Michael R. Hayden,
• Amber L. Southwell

Affiliations

Stefan Bartl

HD Immune, Vienna, Austria; Corresponding authors.

Yuanyun Xie

University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America; University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada

Nalini Potluri

University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America

Ratnesh Kesineni

University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America

Katlin Hencak

University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America

Louisa Dal Cengio

University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada

Katja Balazs

AFFiRiS AG, Vienna, Austria

Abid Oueslati

Centre de recherche du CHU - Universite Laval, Quebec, Canada

Michela Parth

AFFiRiS AG, Vienna, Austria

Nina Salhat

AFFiRiS AG, Vienna, Austria

Alberto Siddu

Centre de recherche du CHU - Universite Laval, Quebec, Canada

Oskar Smrzka

AFFiRiS AG, Vienna, Austria

Francesca Cicchetti

Centre de recherche du CHU - Universite Laval, Quebec, Canada

Günther Staffler

AFFiRiS AG, Vienna, Austria

Michael R. Hayden

University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada

Amber L. Southwell

University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America; Corresponding authors.